AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/22/21

The last few weeks have seen a lot of buyout chatter on AUPH. The CEO made some interesting comments in this regard in their earnings call. I believe the recent drop in price may be an opportunity. For further details see: Aurinia Buyout Chatter: CEO Says To 'Read Betwee...

Aurinia won approval for Lupus Nephritis therapy LUPKYNIS in January this year, causing its share price to reach a high of $19. Analysts believe the drug can achieve >$1bn per annum sales, and longer term, $2bn may not be unrealistic. That has created a slew of recent M&A r...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aurinia Pharma (NASDAQ: AUPH ) stock is taking a beating on Monday following a filing with the U.S. Securities and Exchange Commission (SEC) on Friday. Source: Bukhta Yurii / Shutterstock.com Let’s jump...

Shares of Aurinia Pharmaceuticals (AUPH -28.8%) are down 28% today after filing for a mixed shelf offering late Friday. The offering is for common shares, debt securities, and warrants. Some investors see the offering as sign that a potential buyout of Aurinia may not happen. Last m...

Gainers: iSpecimen (NASDAQ:ISPC) +85%. Navitas Semiconductor (NYSE:NVTSW) +29%. Vonage (NASDAQ:VG) +26%. Astra (NASDAQ:ASTR) +25%. Avaya (NYSE:AVYA) +25%. Lee Enterprises (NASDAQ:LEE) +24%. Cloopen Group (NYSE:RAAS) +24%. MultiPlan (NYSE:MPLN) +23%. Partner (NASDAQ:PTNR) +20%. Camber Energy (...

Aurinia Pharmaceuticals (NASDAQ: AUPH) stock has fallen sharply in response to a recent regulatory filing. Investors feeling queasy about the unlimited shelf registration statement that the company filed on Friday had pulled its share price down by 26.8% as of 10:49 a.m. ET Monday. ...

Gainers: iSpecimen (NASDAQ:ISPC) +120%, MultiPlan (NYSE:MPLN) +21%, Provention Bio PRVB +20%, Stoke Therapeutics (NASDAQ:STOK) +16%, Star Equity STRR +14%. Losers: Gracell Biotechnologies (NASDAQ:GRCL) -31%, Aurinia Pharmaceuticals (NASDA...

Aurinia Pharmaceuticals (NASDAQ:AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in after-hours trading. Aurinia said it plans to use proceeds for clinical development and c...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021. The presentation will be available to all conference attendees...

Bristol Myers Squibb (NYSE: BMY) is reportedly interested in acquiring Aurina Pharmaceuticals (NASDAQ: AUPH) . In this Motley Fool Live video recorded on Oct. 27 , Fool contributors Keith Speights and Brian Orelli discuss whether this deal would be a smart move ...